Issue Date: December 19, 2011
Critics Target Patent Deals
An effort by some members of Congress to restrict pharmaceutical industry deals that critics charge are designed to delay the market entry of low-cost generic drugs has thus far been unsuccessful. But two senators, who aim to curb certain patent lawsuit settlements between brand-name and generic drug makers, are trying a new legislative approach.
“At a time when Americans are struggling to make ends meet, the cost of prescription medications is outpacing inflation. We need . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society